A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 21 Feb 2019
Price : $35 *
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Ankylosing spondylitis; Non-radiographic axial spondyloarthritis; Psoriatic arthritis; Spondylarthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sun Pharma Global FZE
- 13 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 24 Sep 2018 Planned End Date changed from 30 Aug 2022 to 30 Aug 2023.
- 24 Sep 2018 Planned primary completion date changed from 30 Jun 2022 to 30 Jun 2023.